The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a “one size fits all” to an “individualised”...
Source: BMC Ophthalmology - Category: Opthalmology Authors: Jennifer J. Arnold, Caroline M. Markey, Nicol P. Kurstjens and Robyn H. Guymer Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Clinical Trials | Lucentis | Opthalmology | Ranibizumab Injection | Study